Abstract 4066
Background
Breast cancer (BC) represents the most common malignancy and has the highest mortality among women, both in the world and in Kazakhstan. Approximately 20-30% of cases of hereditary breast cancer are caused by presence of BRCA1 and BRCA2 genes defects. Also, there are additional genes which can increase the risk of BC and they are still under study.The aim of this study was to identify new, detectable and objective markers of key cancer genes by next-generation sequencing (NGS) in BC patients.
Methods
The study included 194 unrelated patients (the av/age 34.25 ± 4.56) with BC. Genomic DNA was obtained from peripheral blood,next-generation sequencing was performed using TruSightCancer Kit on the MiSeq platform,studio Variant was used to annotate genetic variants.
Results
In total, 61 pathogenic variants (all in heterozygous state) were found in 56 (28.9%) patients,the vast majority of variants located in BRCA1 (n = 19/56; 33.9%), 15 in BRCA2 (26.8%). The frequency of pathogenic variants in genes TP53 (8.9%), PALB2 (5.4%), MSH6 (5.4%), CHEK2 (3.6%), SDHB (3.6%), and WRN (3.6%) were higher than those genes APC, ATM, FANCA, FANCM, MSH2, NBN, NF1, PMS1, PMS2, and XPA which include only one deleterious variants. The analysis of mutation type has revealed 28 frameshift mutations, 15 stop-gain mutations, 8 missense mutations, 8 splice site variants, 1 start lost variant, and 1 synonymous variant. In total, 43 mutations were unique, 15 of them represented novel variants. Those new mutations have not been previously mentioned in the LOVD and ClinVar databases and have not been described in publications. Population frequency of all detected pathogenic mutations in 1000G, ESP6500 and ExAC databases were less than 1%. 73.8% of the mutations were available in the dbSNP database. The most common pathogenic variants were c.5329dupC and c.5341-2delA (c.5278-2delA) in BRCA1 gene, accounting for 10.7% (n = 6/56) and 8.9% of patients (n = 5/56), respectively.
Conclusions
NGS showed frequent and novel germline mutations in BRCA1/2, CHEK2, TP53 and PALB2. After the final statistical data processing, diagnostic and prevention tools for key genes will be developed and included in the National guidelines for cancer diseases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kazakh Institute of Oncology and Radiology Institute of General Genetics and Cytology.
Funding
The Ministry of Healthcare of the Republic of Kazakhstan.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract
5529 - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Presenter: Robert Tauber
Session: Poster Display session 3
Resources:
Abstract